167 related articles for article (PubMed ID: 2465158)
1. Effects of the specific cholecystokinin antagonist L 364,718 in experimental acute pancreatitis in the rat.
Sjövall S; Ahrén B; Stenram U
Eur Surg Res; 1988; 20(5-6):325-9. PubMed ID: 2465158
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin augmentation of 'surgical' pancreatitis. Benefits of receptor blockade.
Modlin IM; Bilchik AJ; Zucker KA; Adrian TE; Sussman J; Graham SM
Arch Surg; 1989 May; 124(5):574-8. PubMed ID: 2469410
[TBL] [Abstract][Full Text] [Related]
3. Octreotide and cholecystokinin antagonist reduce edema in obstruction-induced acute pancreatitis.
Toriumi Y; Samuel I; Wilcockson DP; Turkelson CM; Solomon TE; Joehl RJ
J Lab Clin Med; 1993 Oct; 122(4):450-4. PubMed ID: 8228560
[TBL] [Abstract][Full Text] [Related]
4. Asperlicin, a nonpeptidal cholecystokinin receptor antagonist, attenuates sodium taurocholate-induced acute pancreatitis in rats.
Wisner JR; Renner IG
Pancreas; 1988; 3(2):174-9. PubMed ID: 2453874
[TBL] [Abstract][Full Text] [Related]
5. Effects of the cholecystokinin receptor antagonist L-364,718 on experimental pancreatitis in mice.
Silverman M; Ilardi C; Bank S; Kranz V; Lendvai S
Gastroenterology; 1989 Jan; 96(1):186-92. PubMed ID: 2462522
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin antagonist prevents hyperamylasemia and improves pancreatic exocrine function in cerulein-induced acute pancreatitis.
Murayama KM; Drew JB; Nahrwold DL; Joehl RJ
Pancreas; 1990 Jul; 5(4):439-44. PubMed ID: 1696383
[TBL] [Abstract][Full Text] [Related]
7. The cholecystokinin receptor antagonist L-364,718 reduces taurocholate-induced pancreatitis in rats.
Kim KH; Lee MG; Kim DG
Int J Pancreatol; 1996 Dec; 20(3):205-11. PubMed ID: 9013282
[TBL] [Abstract][Full Text] [Related]
8. The role of cholecystokinin in the pathogenesis of acute pancreatitis in the isolated pancreas preparation.
Nordback IH; Clemens JA; Cameron JL
Surgery; 1991 Mar; 109(3 Pt 1):301-6. PubMed ID: 1705726
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin analogue and cholecystokinin receptor antagonist on bile-induced acute canine pancreatitis.
Ko TC; Bertram MF; Prinz RA; Castelli M; Djuricin G; Jacobs HK
Am Surg; 1992 Apr; 58(4):213-9. PubMed ID: 1375011
[TBL] [Abstract][Full Text] [Related]
10. Effect of CCK antagonist L 364718 on meal-induced pancreatic secretion in rats.
O'Rourke MF; Reidelberger RD; Solomon TE
Am J Physiol; 1990 Feb; 258(2 Pt 1):G179-84. PubMed ID: 1689547
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of cholinergic-induced pancreatitis with a selective cholecystokinin receptor antagonist.
Bilchik AJ; Zucker KA; Adrian TE; Modlin IM
Arch Surg; 1990 Dec; 125(12):1546-9. PubMed ID: 2244806
[TBL] [Abstract][Full Text] [Related]
12. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice].
Kobayashi M; Shinagawa K; Sugiura M; Nagasawa T; Akahane M; Ajisawa Y
Nihon Yakurigaku Zasshi; 1996 Apr; 107(4):183-95. PubMed ID: 8690301
[TBL] [Abstract][Full Text] [Related]
13. Long-term blockade of cholecystokinin (CCK): effects of L 364,718 (a CCK receptor antagonist) on pancreatic enzyme storage and secretion.
Rodriguez AI; Manso MA; Garcia-Montero AC; Orfao A; de Dios I
Pancreas; 1997 Oct; 15(3):314-22. PubMed ID: 9336798
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin blockade triggers earlier and enhanced intra-acinar oxygen free radical generation in acute pancreatitis induced by pancreatic duct obstruction in rats.
Uruñuela A; Manso MA; de la Mano AM; de Dios I
Clin Sci (Lond); 2003 Aug; 105(2):203-12. PubMed ID: 12713440
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic atrophy in rats produced by the cholecystokinin-A receptor antagonist devazepide.
Nylander AG; Chen D; Ihse I; Rehfeld JF; Håkanson R
Scand J Gastroenterol; 1992 Sep; 27(9):743-7. PubMed ID: 1411279
[TBL] [Abstract][Full Text] [Related]
16. Effects of the cholecystokinin receptor antagonist L-364,718 on pancreatitis induced by a deficient in choline and supplemented with ethionine (CDE) diet in the rat.
Manso MA; Rodriguez AI; Garcia-Montero AC; De Dios I
Arch Physiol Biochem; 1995 Aug; 103(4):410-5. PubMed ID: 8548474
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
18. Effects of early decompression and cholecystokinin inhibition in rats with acute pancreatitis induced by bile-pancreatic-duct obstruction.
de Dios I; Urunuela A; Manso M
J Lab Clin Med; 2003 Apr; 141(4):265-71. PubMed ID: 12677172
[TBL] [Abstract][Full Text] [Related]
19. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
[TBL] [Abstract][Full Text] [Related]
20. Action of CCK on CDE diet-induced acute pancreatitis in rats treated with hydrocortisone.
Manso MA; Rebollo A; Pescador R; de Dios I
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1995 Jun; 111(2):257-63. PubMed ID: 8521247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
